Compare Neurocrine Biosciences Inc (NBIX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while ZIM Integrated Shipping Services Ltd trades at $29.11 (market cap $3.54B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.5× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | ZIM | |
|---|---|---|
Market Cap | $15.77B | $3.54B |
Sector | Health | Industrials |
52-Week High | $185.50 | $30.08 |
52-Week Low | $123.10 | $12.44 |
Enterprise Value | $15.78B | $7.22B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
ZIM Integrated Shipping Services trades at $30.08, up 5.25% with a bullish technical signal from moving averages. The company shows mixed fundamentals with Q2 2026 earnings beating expectations but declining profitability margins year-over-year. Valuation metrics appear attractive with P/S of 0.56 and P/B of 0.93, though analyst sentiment remains divided amid merger uncertainty with Hapag-Lloyd.
The stock faces headwinds from the uncertain $4.2 billion takeover deal and declining net income margins, but strong transpacific positioning and recent earnings beats provide upside potential. Current price sits well above the $18.25 consensus target, suggesting limited near-term upside according to Wall Street analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
